Home > News > PSivida losses almost all due to R&D
August 30th, 2004
PSivida losses almost all due to R&D
pSivida Limited (PSD) today reported that after deducting outside equity interest they had recorded a loss attributable to the members of pSivida of $3.6 million for financial year ending 30 June 2004, compared to a loss of $2.7 million in 2003. The consolidated entity of the global nanotechnology company incurred a net loss of $7.5 million, compared to $5.3 million in 2003. The operating loss includes $7,million in research and development costs expended by pSiMedica and administrative expenses totalling $888,961.
Arrowhead Reports Fiscal 2014 First Quarter Financial Results - Conference Call Today at 4:30 p.m. Eastern Time February 4th, 2014
Arrowhead to Report Fiscal 2014 First Quarter Financial Results - Conference Call Scheduled for Tuesday, February 4, 2014 January 28th, 2014
Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 4, 2014 January 15th, 2014
Nanobiotix 2013 Review: Significant Corporate and Clinical Progress January 7th, 2014